Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any unusual grants.) .... | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10. | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2015 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2015 |
(iii) Distributable Amount for 2015 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2015 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2015 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2015: | ||||
| a | ||||
| b | ||||
| c | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2015 distributable amount | ||||
|
i
Carryover from 2010 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2015 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2015 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2015, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2015. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2016. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a | ||||
| b | ||||
| c Excess from 2013....... | ||||
| d From 2014....... | ||||
| e From 2015....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| ADDITIONAL INFORMATION TO SCHEDULE A, PART I, LINE 4 | MULTI-DISCIPLINARY CENTRE OF ONCOLOGY AT THE UNIVERSITY HOSPITAL CENTRE OF THE CANTON VAUD, LAUSANNE, SWITZERLAND - THROUGH JUNE 30, 2015. UNIVERSITY HOSPITAL CENTRE OF THE CANTON VAUD, LAUSANNE SWITZERLAND AS OF JULY 1, 2015. UNIVERSITY CLINIC OF ST. LUC, BRUSSELS, BELGIUM. AUSTIN HEALTH, MELBOURNE, AUSTRALIA. THE WOMEN'S CHARITABLE SOCIETY OF THE SIRIO-LIBANES HOSPITAL, SAO PAULO, BRAZIL. KAROLINSKA UNIVERSITY HOSPITAL, STOCKHOLM, SWEDEN. UNIVERSITY HOSPITAL, UPPSALA, SWEDEN. MEMORIAL SLOAN-KETTERING CANCER CENTER, NEW YORK, NEW YORK. UNIVERSITY OF CALIFORNIA, SAN DIEGO - SCHOOL OF MEDICINE, SAN DIEGO, CALIFORNIA. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990, PART III | LABORATORY RESEARCH LEADING TO CLINICAL APPLICATIONS - LINE 4A THE LUDWIG INSTITUTE FOR CANCER RESEARCH WAS FOUNDED 45 YEARS AGO AS AN INTERNATIONAL NOT-FOR-PROFIT RESEARCH INSTITUTE DEDICATED TO IMPROVING THE UNDERSTANDING, PREVENTION AND CONTROL OF CANCER. THE INSTITUTE'S SCIENTISTS BOTH CONDUCT INNOVATIVE BASIC RESEARCH AND FACILITATE THE TRANSLATION OF PROMISING CANCER DISCOVERIES INTO APPLICATIONS FOR HUMAN BENEFIT. MAKING MEANINGFUL ADVANCES THAT WILL ULTIMATELY TRANSFORM CARE FOR CANCER PATIENTS IS CENTRAL TO THE INSTITUTE'S MISSION. THE INSTITUTE'S RESEARCH FOCUSES ON ENHANCING THE UNDERSTANDING OF CANCER ONSET AND PROGRESSION, AS WELL AS IDENTIFYING AND CHARACTERIZING TOOLS AND TARGETS FOR NEW DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC MODALITIES. THE LUDWIG INSTITUTE ENGAGES LEADING SCIENTISTS AND CLINICIANS IN AN INTEGRATED LABORATORY AND CLINICAL RESEARCH EFFORT TO CONFRONT THE GLOBAL CHALLENGE OF CANCER. SPECIFICALLY, THE INSTITUTE'S RESEARCH SEEKS TO EXTEND THE KNOWLEDGE OF GENES, PROTEINS, CELLS AND CELLULAR PROCESSES INVOLVED IN CANCER ONSET AND PROGRESSION. THIS UNDERSTANDING OF MOLECULAR AND CELLULAR ABERRATIONS IN CANCER ALLOWS INSTITUTE SCIENTISTS TO FURTHER THEIR LABORATORY WORK TO IDENTIFY, CHARACTERIZE AND EVALUATE NEW TOOLS AND TARGETS FOR THEIR POTENTIAL IN PREVENTIVE, DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. ALL LABORATORY RESEARCH FINANCED BY THE INSTITUTE IS CARRIED OUT BY THE INSTITUTE'S IN-HOUSE RESEARCH STAFF OR THROUGH RESEARCH COLLABORATIONS INVOLVING INSTITUTE STAFF AND EXTERNAL INVESTIGATORS. THE INSTITUTE HAD AROUND 420 SCIENTISTS, CLINICIANS AND SUPPORT PERSONNEL AS OF DECEMBER 31, 2015, LOCATED IN SIX COUNTRIES AND FOCUSED ON MULTIPLE ASPECTS OF CANCER RESEARCH. THE LUDWIG INSTITUTE RECEIVES FUNDING FOR APPROXIMATELY 60% OF ITS RESEARCH COSTS FROM THE LICR FUND, INC., A DELAWARE SUPPORTING ORGANIZATION DEDICATED TO MAINTAINING AN INVESTMENT PORTFOLIO FOR THIS PURPOSE. THIS DEDICATED FUNDING SOURCE GIVES LUDWIG INVESTIGATORS THE FREEDOM TO TACKLE INNOVATIVE LONG-TERM RESEARCH, AND ENCOURAGES AND ENABLES MULTIDISCIPLINARY TEAMS OF INVESTIGATORS TO TACKLE LARGER, MORE COMPLEX CANCER CHALLENGES. THE RESEARCH ACTIVITIES OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH, TOGETHER WITH THOSE OF THE LUDWIG CENTERS ESTABLISHED AT SIX U.S. ACADEMIC INSTITUTIONS WITH FUNDING FROM A TRUST UNDER THE WILL OF DANIEL K. LUDWIG, COMPRISE "LUDWIG CANCER RESEARCH", AN INTERNATIONAL COMMUNITY OF DISTINGUISHED SCIENTISTS DEDICATED TO PREVENTING AND CONTROLLING CANCER. MR. LUDWIG BEGAN TO SUPPORT CANCER RESEARCH WITH THE ESTABLISHMENT OF THE INSTITUTE IN 1971. THE DEVELOPMENT, PROTECTION AND LICENSING OF INTELLECTUAL PROPERTY (IP) GENERATED BY RESEARCH DISCOVERIES AND TECHNOLOGY DEVELOPMENT IS FUNDAMENTAL TO LUDWIG'S COMMITMENT TO TRANSLATE ITS DISCOVERIES INTO APPLICATIONS FOR HUMAN BENEFIT. THE INSTITUTE PATENTS ITS IP TO ENSURE THAT ITS DISCOVERIES ATTRACT INTEREST FROM COMMERCIAL PARTNERS. INCOME FROM THESE ACTIVITIES FINANCED RESEARCH EXPENDITURES AMOUNTING TO USD 6.8 MILLION IN 2015. THE INSTITUTE ALSO MANAGES ITS IP PATENTS FOR PUBLIC BENEFIT. THIS MEANS THE IP IS MADE FREELY AVAILABLE TO THE ACADEMIC RESEARCH COMMUNITY. IN 2015, LUDWIG INSTITUTE INVESTIGATORS PUBLISHED 273 PRIMARY RESEARCH ARTICLES AND 69 REVIEWS, BOOK CHAPTERS AND/OR COMMENTARIES. THESE PUBLICATIONS COVERED A RANGE OF CANCER RESEARCH DISCOVERIES IN THE FIELDS OF GENETICS, GENOMICS, CELL BIOLOGY, SIGNAL TRANSDUCTION, PROTEOMICS, IMMUNOLOGY, BIOINFORMATICS AND DRUG DESIGN DEVELOPMENT. IN 2015, NINE US AND SIX EUROPEAN PATENTS WERE ISSUED; 14 NEW APPLICATIONS WERE FILED IN THE US, ALONG WITH EIGHT NEW INTERNATIONAL PATENT APPLICATIONS. |
| FORM 990, PART III | CLINICAL RESEARCH - LINE 4B LABORATORY RESEARCH ON ISOLATED CELLS AND MACROMOLECULES, WHILE CRITICAL, WILL NOT ALONE PRODUCE THE DIAGNOSTIC AND THERAPEUTIC TOOLS REQUIRED FOR CANCER CONTROL. TO FURTHER UNDERSTAND THE DISEASE AND THE BODY'S REACTION TO IT, AND TO EXPLORE THE THERAPEUTIC POTENTIAL OF DISCOVERIES, CLINICAL RESEARCH - THE ANALYSIS OF PATIENT SAMPLES AND POTENTIAL THERAPIES IN CLINICAL TRIALS - MUST ALSO BE CONDUCTED. RECOGNIZING THIS, THE LUDWIG INSTITUTE TAKES RESPONSIBILITY FOR THE DISCOVERY CONTINUUM, FROM THE LABORATORY THROUGH THE EARLY PHASE CLINICAL TRIALS. THE INSTITUTE BELIEVES THAT THE SAME SYSTEMATIC, INVESTIGATIVE RIGOR THAT YIELDED THE LABORATORY DISCOVERY IN THE FIRST PLACE SHOULD BE APPLIED IN EARLY-PHASE CLINICAL TRIALS TO ASSESS A DISCOVERY'S THERAPEUTIC POTENTIAL. IT HAS, THEREFORE, COMMITTED THE RESOURCES AND MARSHALLED THE CAPABILITIES THAT ALLOW IT TO EVALUATE ITS PROMISING BASIC DISCOVERIES IN HUMAN CLINICAL STUDIES. THE LUDWIG INSTITUTE HAS LICENSING AGREEMENTS WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES THAT ALLOW IT TO OBTAIN PROPRIETARY INVESTIGATIONAL AGENTS AND EVALUATE WHETHER THESE AGENTS MIGHT COMPLEMENT THE THERAPEUTIC POTENTIAL OF THE INSTITUTE'S OWN DISCOVERIES. THE INSTITUTE'S INTERACTIONS WITH INDUSTRY ARE DESIGNED TO PROTECT ITS ETHOS AND INTEGRITY AND TO ENSURE THAT ITS DISCOVERIES ARE ACTIVELY PURSUED AS PROGNOSTIC, DIAGNOSTIC AND/OR THERAPEUTIC AGENTS FOR HUMAN BENEFIT. SEVEN INSTITUTE-SPONSORED CLINICAL TRIALS WERE ONGOING IN 2015. ONE ADDITIONAL STUDY WAS MANAGED BUT NOT SPONSORED DIRECTLY BY THE INSTITUTE. LUDWIG INSTITUTE INVESTIGATIONAL STUDY AGENTS WERE PROVIDED FOR AN ADDITIONAL 19 ACTIVE CLINICAL TRIALS SPONSORED AND MANAGED BY LOCAL ENTITIES. THESE 27 TRIALS WERE SUPPORTED BY 15 ACTIVE INSTITUTE REGULATORY DOSSIERS [EIGHT INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS (USA), ONE DRUG MASTER FILE (DMF), ONE CLINICAL TRIAL APPLICATION (CTA) IN SWITZERLAND AND FIVE CLINICAL TRIAL NOTIFICATIONS (CTN) IN AUSTRALIA]. OVER THE YEAR, THE INSTITUTE MADE FIVE NEW REGULATORY SUBMISSIONS AND 97 SUPPLEMENTAL SUBMISSIONS TO ITS ACTIVE REGULATORY DOSSIERS IN THREE COUNTRIES. |
| FORM 990, PART IV, LINE 12A AND XII, LINE 1 | THE INSTITUTE PREPARED CONSOLIDATED FINANCIAL STATEMENTS IN ACCORDANCE WITH SWISS GAAP FER. THE INSTITUTE PREPARED STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE INSTITUTE PREPARED BRANCH FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS FOR THE FOLLOWING BRANCHES: BRUSSELS (BELGIUM), OXFORD (UNITED KINGDOM), SAN DIEGO (UNITED STATES), SAO PAULO (BRAZIL), STOCKHOLM AND UPPSALA (SWEDEN). THE SUBMITTED RETURN 990 IS BASED ON THE STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE FOLLOWING ACCOUNTING PRINCIPLES APPLY: - CONTRIBUTIONS ARE ACCOUNTED FOR ON THE CASH BASIS - INTEREST IS ACCOUNTED FOR ON THE ACCRUAL BASIS - EXTERNAL FUNDING RECEIVED FROM ANY OUTSIDE SOURCE, WHETHER OF CASH OR A NON-CASH NATURE, IS RECORDED IN THE INSTITUTE'S BOOKS OF ACCOUNT ON RECEIPT. EXTERNAL FUNDING RECEIVED IS TAKEN TO INCOME WHEN THE CORRESPONDING EXPENDITURE IS INCURRED. ANY UNSPENT INCOME IS DEFERRED TO FUTURE ACCOUNTING PERIODS. EXTERNAL FUNDING PLEDGED, BUT NOT RECEIVED WHERE EXPENDITURE HAS BEEN INCURRED, IS TAKEN INTO ACCOUNT AS INCOME AND IS ACCOUNTED FOR AS A GRANTS RECEIVABLE PENDING RECEIPT. - LICENSE FEES AND ROYALTIES ARE ACCOUNTED FOR ON THE MODIFIED CASH BASIS. - EXPENDITURE ON EQUIPMENT AND OTHER ASSETS AND LEASEHOLD IMPROVEMENTS IS CHARGED IN FULL AGAINST REVENUE IN THE YEAR IT IS INCURRED. THE INSTITUTE PREPARED FINANCIAL STATEMENTS IN ACCORDANCE WITH LOCAL ACCOUNTING REQUIREMENTS FOR THE SAO PAULO BRANCH (BRAZIL). THE INSTITUTE PREPARED FINANCIAL STATEMENTS IN ACCORDANCE WITH OFFICE OF MANAGEMENT AND BUDGET CIRCULAR A-133 FOR THE SAN DIEGO BRANCH (UNITED STATES). THE INSTITUTE MAINTAINS ACCOUNTING LEDGERS BY CURRENCY, BY BRANCH, AND BY FUNCTION. INSTITUTE CURRENCIES ARE: AUD, BRL, CHF, EUR, GBP, SEK AND USD. WHEN ANY EXPENDITURE/INCOME OR BALANCE SHEET TRANSACTIONS ARE RECORDED IN THE ACCOUNTS, A NON-INSTITUTE CURRENCY IS CONVERTED INTO AN INSTITUTE CURRENCY AMOUNT USING THE RATE RULING AT THE DATE OF THE TRANSACTION. FOR THE PRODUCTION OF THE STATUTORY FINANCIAL STATEMENTS DENOMINATED IN USD, THE FOLLOWING PRINCIPLES APPLY: NON-USD CONTRIBUTION INCOME IS TRANSLATED INTO USD AT THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. ALL OTHER NON-USD INCOME ITEMS ARE TRANSLATED INTO USD AT THE YEARLY AVERAGE OF THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. NON-USD ASSETS AND LIABILITIES ARE TRANSLATED INTO USD AT THE RATES RULING AT THE END OF THE YEAR. THE RESULTING TRANSLATION ADJUSTMENTS ARE INCLUDED IN THE (DEFICIT)/SURPLUS FOR THE YEAR. |
| FORM 990, PART VI, SECTION A, LINE 2 | BUSINESS RELATIONSHIPS: EDWARD A. MCDERMOTT JR, DIRECTOR AND OFFICER OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD AND DR JONATHAN SKIPPER, OFFICER OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, ALSO SERVE AS OFFICER AND BOARD MEMBER OF LUDWIG TECHNOLOGIES, INC. EDWARD A. MCDERMOTT JR AND RICHARD D.J. WALKER, WHO ARE BOTH OFFICERS OF THE INSTITUTE, ARE ALSO OFFICERS OF LICR FUND. EACH OF THE MEMBERS OF THE BOARD OF DIRECTORS OF THE INSTITUTE IS ALSO A MEMBER OF THE BOARD OF DIRECTORS OF THE FUND. |
| FORM 990, PART VI, SECTION A, LINE 3 | THE LUDWIG GROUP, INC., A 100% SUBSIDIARY OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, PROVIDES MANAGEMENT AND ADMINISTRATIVE SERVICES TO THE INSTITUTE AND RELATED ORGANIZATIONS, INCLUDING PERSONNEL SERVICES AND RELATED FACILITIES AND EQUIPMENT SUPPORT, UNDER FORMAL SERVICE AGREEMENTS WITH THEM. EDWARD A MCDERMOTT JR, DIRECTOR AND PRESIDENT OF THE INSTITUTE, IS EMPLOYED AND COMPENSATED BY THE LUDWIG GROUP, INC. HIS COMPENSATION LISTED ON THE FORM 990, PART VII IS PAID BY THE LUDWIG GROUP, INC. EDWARD A. MCDERMOTT JR'S SERVICES TO THE INSTITUTE ARE BILLED TO THE INSTITUTE BY THE LUDWIG GROUP, INC. |
| FORM 990, PART VI, SECTION A, LINE 6 | THE INSTITUTE IS ORGANIZED AS A SWISS NOT-FOR-PROFIT ORGANIZATION. FORTY-NINE OF THE SHARES ARE HELD BY THE TRUSTEES OF THE LICR CHARITABLE TRUST, A BERMUDA TRUST RECOGNIZED BY THE IRS AS AN EXEMPT SUPPORTING ORGANIZATION OF THE INSTITUTE UNDER SECTIONS 501(C) (3) AND 509(A) (3) OF THE INTERNAL REVENUE CODE, WHOSE PRIMARY PURPOSE IS TO ADMINISTER, DEVOTE AND APPLY ITS ASSETS TO FURTHER THE CHARITABLE AND SCIENTIFIC PURPOSES OF THE INSTITUTE. PURSUANT TO THE PROVISIONS OF THE INSTITUTE'S STATUTES, THE MEMBERS OF THE BOARD OF DIRECTORS ARE NO LONGER REQUIRED TO BE SHAREHOLDERS. FOUR OF THE TRUSTEES OF THE LICR CHARITABLE TRUST ARE MEMBERS OF THE INSTITUTE BOARD OF DIRECTORS. ONE OF THE FOUR TRUSTEES OF THE LICR CHARITABLE TRUST IS ALSO AN OFFICER OF THE INSTITUTE. ONE SHARE IS HELD BY THE SWISS CONFEDERATION. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE STATUTES OF THE INSTITUTE CONFER ON ITS SHAREHOLDERS THE AUTHORITY TO ELECT AND REMOVE MEMBERS OF THE BOARD OF DIRECTORS AND PARTICIPATE IN PROCEEDINGS, DELIBERATIONS, ELECTIONS AND VOTES AT SHAREHOLDER MEETINGS. THE SHARES DO NOT CONFER PROPRIETARY RIGHTS OR ANY ENTITLEMENT TO ANY SHARE OF THE INSTITUTE'S NET INCOME OR CAPITAL OR ANY OTHER ASSETS OWNED OR MANAGED BY THE INSTITUTE. THE INSTITUTE'S STATUTES PROHIBIT THE PAYMENT OF ANY DIVIDENDS OR DISTRIBUTION OF INCOME OR CAPITAL TO THE SHAREHOLDERS. |
| FORM 990, PART VI, SECTION B, LINE 7B | THE SHAREHOLDERS HAVE THE POWER TO GRANT DISCHARGE TO THE MEMBERS OF THE BOARD OF DIRECTORS AND THE EXECUTIVE OFFICERS AT THE SHAREHOLDERS' ANNUAL MEETING FOR THEIR CONDUCT OF BUSINESS. THE ANNUAL FINANCIAL STATEMENTS ARE SUBMITTED TO THE SHAREHOLDERS BY THE BOARD OF DIRECTORS FOR SHAREHOLDER APPROVAL. THE SHAREHOLDERS HAVE THE RIGHT TO MAKE RESOLUTIONS IN RESPECT OF MERGERS, DISSOLUTIONS OR LIQUIDATION OF THE COMPANY AND OF ANY CHANGE OF THE COMPANY'S REGISTERED OFFICE. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE INSTITUTE'S FORM 990 IS REVIEWED AT SEVERAL LEVELS. THE INSTITUTE'S ZURICH OFFICE SENIOR STAFF, THE VICE PRESIDENT, FINANCE LOCATED IN NEW YORK, AND EXTERNAL TAX AND LEGAL COUNSEL REVIEW THE DRAFT FORM 990. FOLLOWING THESE REVIEWS, THE CHAIRPERSON OF THE AUDIT COMMITTEE REVIEWS THE DRAFT RETURN PRIOR TO PRESENTING IT TO THE AUDIT COMMITTEE FOR FURTHER REVIEW. THE FINAL DRAFT OF FORM 990 IS THEN PRESENTED TO THE INSTITUTE'S BOARD OF DIRECTORS PRIOR TO ITS SUBMISSION TO THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE INSTITUTE HAS THREE CONFLICT OF INTEREST POLICIES - RESPECTIVELY FOR THE BOARD OF DIRECTORS, OFFICERS AND STAFF AND A CONFIDENTIAL DISCLOSURE POLICY FOR STAFF. ANNUALLY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS AND STAFF ARE REQUIRED TO DISCLOSE ANY CONFLICTS OF INTEREST. THE CONFLICT OF INTEREST POLICIES FOR THE BOARD OF DIRECTORS AND OFFICERS AND THE CONFIDENTIAL DISCLOSURE POLICY FOR STAFF WERE UPDATED IN 2014 TO REFLECT REQUIREMENTS OF THE NEW YORK NONPROFIT REVITALIZATION ACT OF 2013. BOARD MEMBERS AND EXECUTIVE OFFICERS COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE. ALL OTHER STAFF MEMBERS COMPLETE A CONFIDENTIAL DISCLOSURE FORM. THE COMPLETED QUESTIONNAIRES OF THE MEMBERS OF THE BOARD OF DIRECTORS AND EXECUTIVE OFFICERS ARE REVIEWED BY THE COMPLIANCE AND RISK OFFICER. THOSE CONTAINING ANY DISCLOSURES OR POTENTIAL CONFLICTS OF INTEREST ARE REFERRED TO THE CHAIRPERSON OF THE AUDIT COMMITTEE AND, IF APPROPRIATE, TO THE AUDIT COMMITTEE. AT THE SAME TIME IT IS CONFIRMED TO THE AUDIT COMMITTEE CHAIRPERSON THAT THE OTHER INDIVIDUALS HAD NOT REPORTED ANY DISCLOSURES OR POTENTIAL CONFLICTS OF INTEREST. FOLLOWING THIS ANNUAL DISCLOSURE, IF A CONFLICT OF INTEREST IS SUBSEQUENTLY DEEMED TO EXIST, IT IS THE DUTY OF THE INDIVIDUAL WITH THE CONFLICT TO DISCLOSE IT. FOR ALL CASES WHERE A CONFLICT OF INTEREST EXISTS, THE MATTER IS RECORDED IN THE MINUTES OF THE MEETING OF THE AUDIT COMMITTEE OR THE BOARD. WHERE THE CONFLICT CONCERNS ANY BOARD OR COMMITTEE MEMBER, THE INDIVIDUAL (S) IS (ARE) NOT PERMITTED TO PARTICIPATE IN ANY VOTE OR DELIBERATION ON THE MATTER NOR BE COUNTED IN DETERMINING THE EXISTENCE OF A QUORUM FOR THE PURPOSES OF ANY ACTION OF THE BOARD OR COMMITTEE CONSIDERING THE MATTER. THE ANNUAL DISCLOSURES BY STAFF ARE REVIEWED BY SENIOR MANAGEMENT AND ESCALATED AS NECESSARY. IN ADDITION, DURING THE YEAR, PRIOR TO INVOLVEMENT IN ACTIVITIES THAT COULD BE A POTENTIAL OR PERCEIVED CONFLICT OF INTEREST, INDIVIDUALS ARE REQUIRED TO PROVIDE A WRITTEN DESCRIPTION OF SUCH ACTIVITIES TO A COMMITTEE OF DISINTERESTED OFFICERS. ACTIVITIES DETERMINED TO BE A CONFLICT OF INTEREST THAT ARE NOT MANAGEABLE MAY NOT BE UNDERTAKEN BY THE INDIVIDUAL. FOR ACTIVITIES DETERMINED TO BE A CONFLICT OF INTEREST THAT ARE MANAGEABLE, DETAILS WILL BE SUBMITTED TO THE AUDIT COMMITTEE OF THE INSTITUTE BOARD OF DIRECTORS FOR APPROVAL. |
| FORM 990, PART VI, SECTION B, LINES 15A AND 15B | THE COMPENSATION OF THE MEMBERS OF THE BOARD OF DIRECTORS, THE EXECUTIVE OFFICERS, KEY EMPLOYEES AND FORMER DIRECTORS AND OFFICERS WHO ARE RETAINED AS EMPLOYEES OR CONSULTANTS OF THE INSTITUTE IS SUBJECT TO REVIEW BY THE INSTITUTE'S COMPENSATION COMMITTEE, WHICH CONSISTS OF INDEPENDENT MEMBERS OF THE BOARD. THIS INCLUDES THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER, EDWARD A. MCDERMOTT JR., WHO IS EMPLOYED BY LUDWIG GROUP, INC., WHICH PROVIDES MANAGEMENT SERVICES TO THE INSTITUTE. INDEPENDENT COMPENSATION CONSULTANTS PROVIDE COMPARABILITY SURVEYS TO THE COMMITTEE. ORGANIZATIONS SELECTED FOR PEER ANALYSIS IN THE COMPARABILITY SURVEYS ARE INTENDED TO CAPTURE COMPETITOR ORGANIZATIONS OF SIMILAR SIZE, REVENUE/OPERATING BUDGET AND INDUSTRY RELEVANCE TO LICR. THE STUDIES LAST TOOK PLACE IN DECEMBER 2013, AND ARE CONDUCTED EVERY THREE YEARS. MINUTES OF THE REVIEW AND DECISIONS MADE BY THE COMPENSATION COMMITTEE ARE KEPT AND, ONCE APPROVED BY THE COMMITTEE AT A SUBSEQUENT MEETING, ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. THE COMPENSATION COMMITTEE'S DECISIONS ARE REPORTED TO THE BOARD OF DIRECTORS AND RECORDED IN THE MINUTES OF THE BOARD MEETINGS, WHICH ARE KEPT FOR ALL BOARD MEETINGS. ONCE APPROVED BY THE BOARD AT A SUBSEQUENT MEETING, THE MINUTES OF MEETINGS ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE INSTITUTE MAKES THE FOLLOWING DOCUMENTS AVAILABLE TO THE PUBLIC ON THE WWW.LUDWIGCANCERRESEARCH.ORG WEBSITE: - ANNUAL RESEARCH HIGHLIGHTS - TAX EXEMPT FORM 990 - ANNUAL FINANCIAL REPORTS - CONFLICT OF INTEREST POLICY FOR STAFF MEMBERS - CONFIDENTIAL DISCLOSURE POLICY FOR STAFF MEMBERS - STATEMENT ON SCIENTIFIC INTEGRITY POLICY THE ANNUAL FINANCIAL REPORTS ARE BASED ON THE CONSOLIDATED FINANCIAL STATEMENTS WHICH HAVE BEEN PREPARED IN ACCORDANCE WITH SWISS GAAP FER. GOVERNING DOCUMENTS ARE AVAILABLE ON REQUEST AT THE ADMINISTRATIVE OFFICES IN NEW YORK AND ZURICH, SWITZERLAND. |
| FORM 990, PART VII, SECTION A - LINE 1A | AS PART OF THE ANNUAL PREPARATION OF THE FORM 990, ALL BOARD OF DIRECTORS AND EXECUTIVE OFFICERS PROVIDE AN ESTIMATE OF HOURS WORKED FOR THE INSTITUTE AND THE RELATED ORGANIZATIONS. (SEE PART VII FOR HOURS DEVOTED TO RELATED ORGANIZATIONS.) THE RELATED ORGANIZATIONS REPORT THE RESPECTIVE COMPENSATION FIGURES TO THE INSTITUTE AND PROVIDE COPIES OF THE SUBMITTED W-2 RETURNS/1099 RETURNS. |
| FORM 990, PART VII, SECTION A, LINE 1A AND SCHEDULE J, PART II | BOTH DR. RICHARD KOLODNER AND DR. WEBSTER CAVENEE WERE EMPLOYEES OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD FOR THE FULL YEAR 2015. PRIOR TO HIS APPOINTMENT AS BRANCH DIRECTOR EFFECTIVE JUNE 15, 2015 DR. KOLODNER HELD THE POSITION OF HEAD OF THE LUDWIG LABORATORY OF CANCER GENETICS. SUBSEQUENT TO STEPPING DOWN AS BRANCH DIRECTOR, DR. WEBSTER CAVENEE TOOK UP THE POSITION OF DIRECTOR OF STRATEGIC ALLIANCES IN CENTRAL NERVOUS SYSTEM (CNS) CANCERS. THE COMPENSATION REPORTED FOR THESE TWO INDIVIDUALS IS COMPENSATION FOR THE FULL YEAR 2015. |
| FORM 990, PART XI, LINE 9 | OTHER CHANGES IN NET ASSETS: NET LOSS ON FOREIGN EXCHANGE DUE TO OPERATIONS : ($2,071,864) REVERSE NEGATIVE GRANTS : (24,882) NET FOREIGN EXCHANGE GAIN ON CAPITAL & LEGAL RESERVE : 208 --------------- ($2,096,538) |
| FORM 990, PART VI, LINE 4 - SIGNIFICANT CHANGES TO BYLAWS | THE BOARD OF DIRECTORS OF THE INSTITUTE ADOPTED REVISED BY-LAWS AT ITS BOARD MEETING ON DECEMBER 8, 2015, WHICH BECAME EFFECTIVE AS OF JANUARY 1, 2016. AS FROM THAT DATE THE EXECUTIVE DIRECTOR OF OPERATIONS POST WAS DELETED. THE POSTS OF EXECUTIVE DIRECTOR OF COLLABORATIVE SCIENCES AND - TECHNOLOGY DEVELOPMENT WERE REDESIGNATED TO EXECUTIVE VICE-PRESIDENT, RESPECTIVELY EXECUTIVE VICE-PRESIDENT FOR RESEARCH AND EXECUTIVE VICE-PRESIDENT FOR TECHNOLOGY-DEVELOPMENT. |
| Software ID: | |
| Software Version: |